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Haemorrhage in the setting of severe trauma is associated with significant morbidity 
and mortality. There is increasing awareness of the important role fibrinogen plays in 
traumatic haemorrhage. Fibrinogen levels fall precipitously in severe trauma and the 
resultant hypofibrinogenaemia is associated with poor outcomes. Hence, it has been 
postulated that early fibrinogen replacement in severe traumatic haemorrhage may 
improve outcomes, although, to date there is a paucity of high quality evidence to 
support this hypothesis. In addition there is controversy regarding the optimal 
method for fibrinogen supplementation. We review the current evidence regarding 
the role of fibrinogen in trauma, the rationale behind fibrinogen supplementation and 
discuss current research. 
 
 
Abbreviations: A5 (A10) = amplitude of clot firmness 5 (10) minutes after CT, BW = 
body weight, CFT = clot formation time, Cryo = cryoprecipitate, CT = clotting time, 
DCR = damage control resuscitation, ED = Emergency Department, FC = fibrinogen 
concentrate, FibC = Clauss Fibrinogen, FFP = fresh frozen plasma, GCUH = Gold 
Coast University Hospital, Queensland, Australia, Hb = Hemoglobin, iCa = ionized 
Calcium, ICU = intensive care unit, MCF = maximum clot firmness, MHP = major 
haemorrhage protocol, OR = operating room, rPT = rapid Prothrombin Time, POC = 
Point of Care, PRBC = packed red blood cells, PT = Prothrombin Time SLT = 
standard laboratory test, Temp = core temperature, TIC = trauma-induced 
coagulopathy, TXA = tranexamic acid, VHA = viscoelastic hemostatic assays 
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Trauma is a leading cause of death worldwide in individuals aged 18-39 years and 
represents a major global health concern (1). Despite advances in trauma 
management, a significant proportion of these deaths are secondary to haemorrhage 
and preventable (2) (3) (4). In patients where surgical haemorrhage control is 
achieved, subsequent morbidity and mortality is often attributed to coagulopathy 
complicated by organ failure due to the effects of major haemorrhage and large 
volume blood product transfusion (5) (6) (7). Death related to major haemorrhage is 
potentially preventable and represents a target for mortality reduction strategies. 
There is increasing awareness regarding the critical role of fibrinogen in traumatic 
haemorrhage. The objectives of this review are to examine the available evidence 




A literature search was performed on major databases including PubMed, Medline, 
Embase, Web of Science and ClinicalTrials.gov. Search terms included “fibrinogen”, 
“trauma”, “transfusion protocols”, “massive transfusion”, “cryoprecipitate”, “fibrinogen 
concentrate”, “viscoelastic testing”, “ROTEM” and “TEG”. Titles and abstracts were 
reviewed and full text articles retrieved for inclusion if considered relevant. Additional 
articles were identified from reference lists of identified articles.  Database searches 
were supplemented by private files/collections of the authors, and a grey literature 
search using Google scholar.  Results are presented in a narrative form. 
 
Role of Fibrinogen in Trauma Induced Coagulopathy: 
 
Severe trauma may be complicated by a unique, complex and multifactorial 
coagulopathy – Trauma Induced Coagulopathy (TIC); of which the exact 
pathophysiological mechanisms are yet to be elucidated (8) (9) (10) (11).  TIC is 
characterized by reduced clot strength related to hypo/dysfibrinogenaemia, platelet 
dysfunction, hyperfibrinolysis and endothelial dysfunction (12). Central to the 
proposed mechanism is the effect of direct tissue injury and hypoperfusion on the 
endothelium resulting in systemic anticoagulation and hyperfibrinolysis (13). TIC may 
subsequently be exacerbated by acidosis, hypothermia, haemodilution and factor 
consumption (14) While the exact mechanisms are debated, patients with TIC do 
certainly have significantly increased transfusion requirements and mortality (15) 
(16). 
 
The role of fibrinogen in maintaining effective haemostasis is widely accepted (17). 
Fibrinogen is a glycoprotein synthesised in the liver and is the key final component of 
the clotting cascade; forming fibrin – an insoluble protein that is the foundation of a 
stable clot (18). Fibrinogen is cleaved by Thrombin to fibrin monomers, which are 
polymerised and subsequently stabilised by activated Factor XIII to form a fibrin clot 
(19). Fibrinogen is also fundamental in the aggregation of activated platelets through 
the glycoprotein IIb/IIIa receptors. The healthy adult has a plasma fibrinogen 
concentration of between 2 to 4g/L (20).  
 
In traumatic haemorrhage, there is increasing evidence supporting the important role 
fibrinogen plays in effective clot formation. Lower levels of fibrinogen and increased 
fibrinogen breakdown are key features of TIC (21) (22). Fibrinogen is the first factor 
to fall below reference values during bleeding and in trauma reaches critically low 
levels earlier than any other coagulation factors (23). This has been demonstrated in 
both the pre-hospital environment and early after arrival in the trauma unit prior to 
large volume fluid resuscitation (24) (25). In a number of studies the degree of 
hypofibrinogenaemia is strongly associated with injury severity (22) (26). This 
suggests fibrinogen deficiency is innately related to the primary and secondary 
physiological insults induced by severe trauma. Subsequently, further 
hypofibrinogenaemia occurs as a consequence of major blood loss, consumption, 
dilution, acidosis and hypothermia (27) (28) (29) (30). In addition, the fibrin strands 
that form in a low fibrinogen environment are more susceptible to fibrinolysis and a 
number of studies report hypofibrinogenaemia in the presence of hyperfibrinolysis 
(31) (32) (33).  Hyperfibrinolysis in the setting of severe trauma is a central 
component of TIC and although relatively rare is associated with poor outcomes (34) 
(35) (36). The association between hypofibrinogenaemia and worse outcomes in 
severe trauma has been well demonstrated although to date the pathophysiological 
mechanisms remain incompletely understood (22) (37) (38).     
 
Major Haemorrhage Protocols (MHP): 
 
Major Haemorrhage Protocols utilised by many trauma centres are activated once 
significant haemorrhage is suspected. In addition to rapid surgical control of 
haemorrhage, the MHP involves the empiric and early delivery of a predefined fixed-
ratio transfusion of blood products (Plasma, Platelets and PRBC), in an attempt to 
ameliorate the coagulopathy associated with major haemorrhage and large volume 
blood transfusion (39) (40). MHP have been implemented in response to studies 
showing that in massive transfusion the inadequate replacement of coagulation 
factors is associated with poor outcomes (41). Whilst it is clear that the institution of 
a MHP does improve outcomes, the optimal ratio of blood components to PRBC 
remains the focus of considerable debate (42) (43) (44) (45) (46).  
 
The PROMMTT study provided initial data to support a high product to PRBC 
transfusion ratios in trauma MHP (1:1:1 Plasma:Platelets:PRBC) (47). The survival 
advantage postulated to be due to earlier replacement of consumed factors 
mitigating the effect of TIC and that the replacement physiologically more closely 
approximates to what is being lost. However, even in high ratios the delivered 
replacement is potentially dilute in terms of factors (39). The subsequent Pragmatic 
Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial reported no 
difference in survival between a 1:1:1 or 1:1:2 transfusion strategy but more patients 
in the 1:1:1 group achieved haemostasis and fewer died from exsanguination (48). A 
number of studies have reported that in patients receiving higher ratios there is an 
increase in the amount of plasma transfused and an increased incidence of 
transfusion-related adverse events without a survival benefit, however, these 
concerns were not confirmed in the PROPPR trial (49) (50) (51). Time to delivery of 
product replacement in PROPPR was rapidly achieved without significant wastage 
but this is dependent on having thawed product available 24 hours a day in either the 
trauma unit or blood bank (52). The impressive delivery of blood component therapy 
as described in the PROPPR trial may be difficult to translate into routine clinical 
practise (53). A recent study from Stanworth et al. reports widespread variations in 
patterns of blood product delivery across a number of trauma centres, with few 
patients receiving an ‘optimal’ product ratio (54). 
 
Fibrinogen Replacement as part of a MHP: 
 
Hypofibrinogenaemia after severe trauma is associated with increased risk of both 
massive transfusion and mortality (37) (55). It is postulated that early fibrinogen 
replacement may be efficacious in correction of coagulopathy, assist in haemorrhage 
control and decrease transfusion requirements (37) (56) (57) (58). Two studies from 
the military indicate that maintaining higher fibrinogen levels as part of a MHP is 
associated with improved survival (59) (60).  
 
Empiric and early fixed ratio delivery of specific fibrinogen containing products is not 
standard practice in the majority of MHP. Whilst plasma does contain fibrinogen it is 
in a concentration and volume that is potentially too dilute in terms of adequacy of 
replacement. The mean fibrinogen concentration in plasma is approximately 2g/L 
and large volumes of plasma (+/- 30ml/Kg) are required to adequately supplement 
fibrinogen (61). In most MHP the transfusion of additional fibrinogen in the form of 
cryoprecipitate usually occurs only late in the protocol and in response to low plasma 
fibrinogen levels as measured by laboratory tests of plasma fibrinogen. There are 
inherent problems with this approach resulting in significant delays to effective 
administration of fibrinogen. In addition there is significant debate regarding at what 
level of plasma fibrinogen should trigger additional fibrinogen replacement. The 
majority of current guidelines would suggest that plasma fibrinogen levels of < 1 – 
1.5g/l should trigger additional fibrinogen, however, this is not based on solid 
evidence (62) (63). Hagemo et al, have demonstrated an increased mortality in 
trauma patients with fibrinogen levels below 2.29g/l (22). In severe trauma fibrinogen 
levels should potentially be maintained at levels higher than currently recommended. 
The 2016 European Trauma Guidelines recommend fibrinogen supplementation if 
thromboelastometric signs of functional fibrinogen deficiency or plasma fibrinogen 
levels < 1.5 – 2g/l (64). 
 
Fibrinogen can be replaced with: fibrinogen concentrate (FC), cryoprecipitate or 
plasma, each containing different amounts of fibrinogen: 20g/L, 8-16g/l and 2g/L, 
respectively, and therefore different volumes are required to achieve replacement 
(65). A study by Rourke et al. (37) demonstrated that standard protocol driven 
transfusion ratios were ineffective in maintaining fibrinogen levels and the addition of 
cryoprecipitate was required. Khan et al. (66) showed that high dose plasma 
transfusion does not correct TIC and coagulation parameters only improve with 
plasma, cryoprecipitate and platelet transfusion with a combined high fibrinogen 
load. Chambers et al. (67) report that 1:1:1 MHP does not affect the frequency or 
duration of coagulopathy as measured by standard coagulation tests and 
hypofibrinogenaemia was almost always the first abnormality detected. 
 
The PROMMTT study described wide variability in cryoprecipitate transfusion 
practices in 10 American Level 1 trauma centres; in those patients receiving 
cryoprecipitate the median time to transfusion was 2.7 hours and the majority of 
those patients who died of haemorrhage did not receive cryoprecipitate (68). These 
findings are supported by a recently published study from the UK investigating 
transfusion practices in traumatic haemorrhage - the median time to delivery of 
cryoprecipitate as part of a MHP was more than 2 hours and almost 50% of patients 
did not receive cryoprecipitate as part of their initial resuscitation (54). This is 
concerning, considering that the median time to death from haemorrhage is reported 
to be approximately 2.6 hours (48) (54).  
 
The CRYOSTAT study, recently published by Curry et al. (69), demonstrated that the 
early administration of cryoprecipitate as part of a MHP is feasible in trauma patients. 
85% of patients randomised to the Cryo arm received cryoprecipitate within 90 
minutes and the median time to transfusion was 60 minutes. Additionally, fibrinogen 
levels were consistently higher throughout active haemorrhage in the Cryo arm.  
 
The ideal trauma MHP remains elusive and a number of key questions remain 
unanswered. Amongst these are: 1) Which laboratory tests and what triggers should 
be used to guide resuscitation 2) What is the impact of early fibrinogen replacement 
on haemostasis and clinical outcomes (46). 
  
Assessment of TIC: Standard Laboratory Tests (SLT) 
 
The diagnosis of TIC is conventionally made using prothrombin time (PT) and 
activated partial thromboplastin time (APTT). These tests, performed on platelet poor 
plasma were developed to determine single factor deficiencies and effects of 
anticoagulant therapy. They are poor predictors of bleeding in trauma and due to 
time delay to result availability fail to provide contemporary information (70) (71).  
Neither the PT nor APTT give an indication of the fibrinogen contribution to clot 
strength or quality. There are number of laboratory test utilised to quantify plasma 
fibrinogen levels, the two most common are; Clauss Fibrinogen (FibC) and 
Prothrombin Time (PT) Derived Fibrinogen. In the FibC test, concentrated thrombin 
is added to dilute plasma, converting fibrinogen to fibrin and the clotting time is 
inversely proportional to the amount of fibrinogen. In the PT-Derived Fibrinogen the 
difference between baseline and maximum turbidity is proportional to fibrinogen 
concentration (72) (73). The tests should not be used interchangeably as there can 
be significant discrepancies between PT-derived fibrinogen and FibC (74). There can 
be significant variations in reproducibility and consistency in fibrinogen levels 
between laboratories utilising either test due to differences in; type of analyser, read 
out method (photo-optical or electromechanical), software and brand of assay used 
(75). The use of artificial colloids can also falsely elevate the fibrinogen level 
reported by both tests (72) (76) (77). However, this is unlikely to be of major concern 
in Australia, where the use of artificial colloids is not usual standard practice. The 
major limitation in utilising either test for assessment of fibrinogen concentration in 
severe trauma is the time delay to result availability, which can be greater than 60 
minutes (78). An emergency haemorrhage panel utilising standard laboratory tests 
(including fibrinogen) with modifications to sample centrifuging, assays and 
calibration ranges is reported to be available in approximately 20 minutes (79). 
However, this is not routinely available in Australia and may be difficult to implement 
into routine clinical practice. 
 
Assessment of TIC: Viscoelastic Haemostatic Assays (VHA): 
 
An alternative to SLT, utilises viscoelastic haemostatic assays (VHA) to rapidly 
identify coagulation defects and potentially guide targeted interventions (80) (81) (82) 
(83) (84). Two commercially available devices: TEG® (Haemonetics, Braintree, MA, 
USA) and ROTEM® (TEM International GmbH, Munich, Germany) are in widespread 
use; neither is superior and utilisation differs geographically (85) (86) (87). In our 
institutions the ROTEM® device is utilised; some information is summarised in 
Figures 1 and 2. VHA measure clot formation up to and including fibrinolysis in 
contrast to SLT, which document the beginning of fibrin formation when only 5% of 
total thrombin has been generated. VHA provide information regarding time to clot 
formation, clot strength and clot lysis; enabling different components of the 
coagulation cascade and their respective contribution to the clot kinetics to be 
assessed (85) (88) (89).  
 
VHA have higher sensitivity for the detection of traumatic coagulopathy and provide 
results more rapidly than SLT (78) (90) (91) (92). In a study by Holcomb et al. (93) 
involving almost 2000 patients, Thromboelastography (TEG) was found to be 
superior to SLT across a number of parameters. The use of point of care (POC) 
rapid PT (rPT) devices can be utilised as an initial tool to assess coagulopathy but 
their utility remains controversial. A recent paper by Goodman et al, has suggested 
that POC rPT can be utilised as an alternative to r-TEG, reporting that rPT is 
cheaper and faster than r-TEG with similar diagnostic accuracy (94). In contrast, 
Davenport et al, report that although available quickly, the point of care rPT results 
are inaccurate with significant discrepancies to laboratory PT (78). The rPT may give 
an indication of the development of TIC and risk of subsequent massive transfusion 
but neglects the contribution of fibrinogen to clot strength (71). VHA have been 
incorporated into a number of trauma management guidelines and a number of 
trauma centres utilise targeted protocols in addition to or in place of fixed ratio MHP 
(64) (95) (96) (97). Inaba et al, have recently published a consensus statement 
based on expert opinion and extensive systematic literature review regarding VHA 
guided treatment triggers for blood product transfusion in severe trauma (81).   
 
However, despite the growing evidence base to support the use of VHA in guiding 
blood product therapy in traumatic haemorrhage, data from randomised controlled 
studies is limited (57) (96) (98) (99) (100). A recent Cochrane Review concluded that 
there is an expanding evidence base that the application of VHA guided transfusion 
strategies can improve morbidity in bleeding patients (101). However, the quality of 
studies was low, the majority of trials were in cardiac surgical patients and further 
high quality studies in acute haemorrhage are required.  
 A recently published single centre randomised controlled trial reported significant 
reduction in blood product transfusion rates and improved survival with a TEG 
guided MHP (97). The multi-centre, prospective randomised controlled iTACTIC Trial 
(NCT:02593877) investigating the use of VHA in traumatic haemorrhage is currently 
recruiting in Europe. Patients randomised to the intervention arm will receive MHP 
resuscitation (1:1:1) with subsequent VHA (ROTEM® or TEG®) guided blood 
product and pro-coagulant factor administration; the control arm will receive the 
same 1:1:1 MHP resuscitation with subsequent blood product and pro-coagulant 
transfusion guided by standard laboratory tests. The primary outcome is proportion 
of patients alive and free of major haemorrhage at 24 hours. The trial will recruit 
about 400 patients and is aiming to complete at the end of 2017.   
 
It has been suggested that there can be quality control and standardisation issues 
associated with point of care viscoelastic testing assays; with variability in test results 
between different devices, operators and centres (102) (103). It is important that 
institutions operating viscoelastic devices in the point of care setting should be 
involved in external quality assurance programmes (104) (105) (106).  
 
Rapid Fibrinogen Assessment Utilising VHA: 
 
Specific assays in both ROTEM® and TEG® are available to rapidly assess 
fibrinogen contribution to clot strength. In both assays the clot kinetics are assessed 
in the presence of a platelet inhibitor; FIBTEM (ROTEM®) – Cytochalasin D and 
Functional Fibrinogen [FF] (TEG®) - Abciximab.  The FIBTEM and FF assays can be 
utilised to rapidly identify those patients in whom hypo/dysfibrinogenaemia is 
contributing to on-going haemorrhage (55) (95) (107) (108). The FIBTEM and FF 
correlate well with standard laboratory measurements of fibrinogen concentration in 
a number of clinical situations (109) (110) (111) (112) (113).  
 
There is good quality evidence to support the use of the FIBTEM assay as a marker 
of TIC and in predicting massive transfusion in severely injured trauma patients (90). 
There is increasing evidence to support the use of the FIBTEM assay as a strategy 
to decrease blood product transfusion in a variety of clinical settings (98) (114) (115) 
(116) (117). However, these findings have not been confirmed by high quality studies 
in the severely bleeding trauma patient.  
 
To optimize capacity to correct coagulopathy rapidly, clot firmness amplitude results 
obtained at five minutes after clot formation (A5) can be used (55) (107) (118). A5 
results have been found to correlate very well with maximum clot firmness (MCF) 
results in a number of clinical settings (118). Rapidly available real time results 
potentially permit targeted fibrinogen supplementation to those patients that need it 
rather than in a fixed-ratio MHP manner or in response to standard laboratory tests. 
The approach to fibrinogen replacement in our institution is demonstrated in Figures 
3 and 4. 
 
Cryoprecipitate for Fibrinogen Replacement: 
 
Cryoprecipitate has been in use for more than 50 years and was originally developed 
as a treatment for patients with Haemophilia A (119). Each unit of cryoprecipitate is 
prepared from 1 unit of FFP; thawed at 1-6oC, centrifuged to remove the excess 
cryodepleted plasma, re-suspended in 30-40ml of residual plasma and refrozen at -
18oC. Although each unit of cryoprecipitate contains a high concentration of 
fibrinogen due to the small volume, the process recovers only 30% of fibrinogen from 
the plasma unit. In addition cryoprecipitate contains the other clotting factors - FVIII, 
vWF and FXIII. Cryoprecipitate is now almost exclusively used to replace fibrinogen 
in patients with acquired hypofibrinogenaemia – often in the setting of critical 
bleeding (120).  
 
Cryoprecipitate use in severe trauma accounts for up to 30% of all units transfused 
(121) (122). There is widespread variability in the recommended dose of 
cryoprecipitate (ranging from 10 to 20 units) and little conformity between 
professional institutions (62). There is little high level evidence to support these 
dosing recommendations and reasons for this variability are twofold. Firstly, the 
concentration of fibrinogen in cryoprecipitate varies significantly between countries 
and institutions, ranging from 3-30g/l (62). In a Canadian study, cryoprecipitate units 
prepared in the same institution had fibrinogen concentrations ranging from 3.2 to 
8.2g/l (123). The majority of regulatory authorities state that each unit of 
cryoprecipitate should contain at least 150mg of fibrinogen. Secondly and directly 
linked to the variability in fibrinogen per unit of cryoprecipitate, is the variable dose 
response to cryoprecipitate as determined by plasma fibrinogen levels. It is reported 
that the transfusion of 10U cryoprecipitate should increase the plasma fibrinogen by 
approximately 1g/l (124). However, in the trauma setting it has been reported that a 
dose of approximately 9U cryoprecipitate resulted in a mean increase in plasma 
fibrinogen of only 0.55g/l (125). The majority of guidelines recommend dosing of 
cryoprecipitate in response to low plasma fibrinogen levels. This is impractical in the 
setting of severe bleeding where delays to effective transfusion of cryoprecipitate are 
compounded by the time taken to prepare and procure the requested units. A 
number of papers report the ‘inappropriate’ transfusion of cryoprecipitate i.e. not 
given in response to plasma fibrinogen levels  (121) (122) (125) (126). It is likely that 
the delays in obtaining plasma fibrinogen results combined with time to prepare 
requested units, results in clinicians empirically ordering and transfusing 
cryoprecipitate on clinical grounds rather than as per published guidelines. The use 
of cryoprecipitate in traumatic haemorrhage varies widely between institutions and 
there are often significant delays to effective transfusion (54). The CRYOSTAT study 
has demonstrated that it is possible to transfuse cryoprecipitate early and empirically 
as part of a MTP, however, the median time to administration was still 60 minutes 
(69).  
 
Cryoprecipitate (for fibrinogen replacement) has been withdrawn from use in many 
European countries due to safety concerns and has been replaced with Fibrinogen 
Concentrate (127) (128). A standard dose of cryoprecipitate is sourced from multiple 
donors, therefore potentially increasing the risk of pathogen transmission and 
transfusion related adverse events (129). 
 
Cryoprecipitate is widely accepted as the standard of care for fibrinogen 
supplementation in severe haemorrhage; however, there is a lack of good quality 
evidence to support this strategy. It has been suggested, in view of the fact that 
cryoprecipitate is not virus-inactivated, is dosed in multiple units, with a lack of 
quality evidence to support its use and that there are potentially safer alternatives 
available, it is unlikely that regulatory approval would be granted for its use today 
(62) (128).   
 
Fibrinogen Concentrate for Fibrinogen Replacement: 
 
There are a number of theoretical advantages to the use of FC; reduction in volume 
required, standard dose per vial, lack of variability in fibrinogen concentration, no 
requirement for ABO compatibility matching, viral inactivation, stored at room 
temperature, easily reconstituted and administered. However, in severe trauma there 
are no robust clinical trials demonstrating a survival or cost effectiveness benefit to 
the use of FC compared to cryoprecipitate (21) (63) (130) (131) (132).  
There is increasing evidence supporting the important role of fibrinogen and the use 
of FC in other clinical situations with severe haemorrhage – cardiac surgery, 
obstetric haemorrhage and general surgery (133) (134) (135) (136) (137). Recent 
systematic reviews on the management of major haemorrhage and the use of 
fibrinogen supplementation suggest potential positive benefits but conclude more 
research is required (21) (138) (139). A Cochrane review evaluating the 
effectiveness of FC in severe haemorrhage reported six trials of moderate quality 
that were underpowered for mortality benefit detection but did demonstrate reduction 
in allogeneic transfusion requirements (140).  
 
There is expanding observational evidence to support the use of FC in the setting of 
severe trauma and a number of studies have reported; increased clot strength, 
reduction in blood loss, reduced transfusion of allogenic blood products and 
reduction in mortality in patients treated with FC (96) (57) (98) (99) (141). Although 
promising, the majority of publications are observational or retrospective cohort 
studies and do not provide high level evidence to support FC use in severe trauma.  
 
A major concern regarding early fibrinogen replacement utilising FC is the potential 
for subsequent thromboembolic complications. This is of particular concern in 
severely traumatised patients who are at significant risk of this complication. A 
number of animal studies using models of traumatic coagulopathy provided initial 
safety data in favour of FC (142) (143) (144). Subsequently, a recently published 
pharmaco-vigilance study suggests that FC is not associated with increased 
thromboembolic complications; data from over 2.5 million grams of FC 
(approximately 600,000 standard doses of 4g) distributed over a 27 year period 
reported possible thromboembolic events in 28 cases (1 per 93,300 grams or 1 per 
23,300 doses) (145). A comprehensive systematic review evaluating FC use in the 
perioperative setting concluded that there was no significant increase in thrombotic 
events in FC treated patients (146). Schochl et al. report in a cohort of severely 
injured trauma patients, that even after large doses of FC, subsequent plasma levels 
of fibrinogen did not exceed normal expected ranges and that there was no 




The optimum dosing schedule of fibrinogen is controversial with widespread 
variability in recommendations from different professional bodies (62) (147) (148). 
European guidelines for massive haemorrhage in severe trauma recommend FC 3-
4g or Cryoprecipitate 50mg/kg to restore fibrinogen levels (64). Taneka et al, 
describe in detail the rationale behind cryoprecipitate and FC dosing (149). Collins et 
al, have published a theoretical model of fibrinogen dosing with plasma, 
cryoprecipitate and FC (65). Although this model is not designed for clinical use it 
does highlight the significant differences in volume of product potentially required to 
achieve effective fibrinogen supplementation. One of the potential advantages of 
using FC is the standardised fibrinogen concentration per vial (+/- 1g); making 
dosing and assessment of dose response easier than when utilising cryoprecipitate, 
which has a very wide variability in fibrinogen content per unit (131). Dosing 
strategies for FC using VHA have been suggested in the cardiac surgical patient 
population (150). In traumatic haemorrhage a few animal studies have suggested 
potential dosing strategies but there is a paucity of quality human data (151) (152).  
 
Published data and local institutional data suggest that 1g of Fibrinogen (FC or 
Cryoprecipitate) will result in an increment of between 1.5 and 2mm in the FIBTEM 
assay (123) (150) (153). This is in line with published data suggesting that a 1g dose 
of fibrinogen will result in a plasma fibrinogen increment of 0.25g/l (56) (135) (154). 
Due to the variability in fibrinogen concentration in cryoprecipitate, including frequent 
loss of units to breakage during thawing, accurate dosing is more feasible with FC. 
Our local data supports the published literature in equating 1g of FC to between 3 
and 5 single Units of cryoprecipitate (149). The recently completed but not yet 
published FIinTIC trial (NCT01475344) may provide guidance on appropriate FC 
dosing; this study utilised a weight based FC dosing strategy in the pre-hospital 
environment with fibrinogen levels on arrival to ED as the primary endpoint (155). 
 
A recent publication from the AUVA Trauma Centre demonstrated that patients 
treated with FC did not have higher plasma fibrinogen levels than the control group 
of trauma patients not treated with FC in the post trauma phase (up to day 7) (156). 
Suggesting that despite relatively high doses of FC there is no ‘overshoot’ in plasma 
fibrinogen levels beyond expected levels subsequent to severe injury. All patients 
exhibited a rise in plasma fibrinogen levels post trauma that can be attributed to 
increased hepatic synthesis as part of the acute phase response to severe trauma. 
These findings are supported by the CRYOSTAT study; where there was no 
excessive rise in plasma fibrinogen levels or increased risk of thromboembolic 
complications with fibrinogen supplementation using cryoprecipitate therapy (69).  
 
 
Fibrinogen Trials in Non-Traumatic Haemorrhage: 
 
The use of Fibrinogen Concentrate has been extensively investigated in randomised 
controlled trials in patients with post-partum haemorrhage and those undergoing 
cardiac surgery. In the recently published FIB-PPH study, women with post-partum 
haemorrhage (PPH) were randomised into receiving either 2g FC or placebo, after 
clinical suspicion of significant PPH (>1.5L) (157). There was no difference in any of 
the primary outcomes between the two groups. However, the data presented 
showed that the mean plasma fibrinogen level in both groups was > 4g/l and 
therefore hypofibrinogenaemia was unlikely to be contributing to bleeding. The 
REPLACE study; investigating FC use in cardiac surgery has recently been 
published (158). This study randomised patients to FC or Placebo with a 5 minute 
bleeding mass of >60g after separation from cardio-pulmonary bypass. The study 
reported increased allogenic blood product requirements in the FC arm. This was a 
surprising finding which was incongruent with the results of the pilot single centre 
studies and a full explanation is not clear. It is postulated that the low observed 
bleeding rates, use of the 5 minute bleeding mass (not routinely used in clinical 
practice), normal range plasma fibrinogen levels and a complex treatment algorithm 
all contributed to the unexpected results of the trial.    These studies suggests that 
based on purely clinical indications it is difficult to predict which patients may benefit 
from fibrinogen supplementation and there is no benefit to fibrinogen 
supplementation in patients with normal fibrinogen levels. 
 
A single “one-off” dose of additional fibrinogen supplementation “one size fits all 
approach” may not be appropriate and it is possible that fibrinogen replacement may 
better be guided by the degree of hypofibrinogenaemia to avoid potential under and 
over dosing. In a recent study investigating fixed dose fibrinogen concentrate 
supplementation in cardiac surgery – The Zero Plasma Trial (ZEPLAST), it was 
shown that a fixed dose of 6g FC reduced post-operative bleeding and blood product 
transfusion (159). However, subsequent data analysis revealed that a reduced dose 
of FC would have likely yielded the same results (160). It would seem to make 
intuitive sense to dose fibrinogen replacement based on degree of 
hypofibrinogenaemia.   
 
Fibrinogen Trials in Traumatic Haemorrhage: 
 
There is increasing recognition and good evidence to support of the importance of 
fibrinogen in effective clot formation in severe traumatic haemorrhage. The utility of 
early fibrinogen replacement using FC and/or cryoprecipitate is gaining popularity but 
at the current time is not supported by high quality evidence (161). In the last decade 
there has been a vast amount of literature published regarding traumatic 
coagulopathy and transfusion strategies. However, the quality of evidence remains 
low as many of the reported studies contain significant methodological and statistical 
flaws (162).  
 
The heterogeneous nature of injury pattern, the complex nature of traumatic 
coagulopathy and the geographical variation in clinical practice makes performing 
studies logistically challenging (163). Although individual patient randomised 
controlled trials in trauma present unique challenges to investigators, they are 
possible to perform successfully (48) (69). Two large multi-centre RCT’s in bleeding 
civilian trauma patients have shown that outcomes can be improved with rapid 
haemostatic intervention. The CRASH-2 trial demonstrated a significant survival 
benefit in trauma patients treated with Tranexamic Acid within 3 hours of injury (164). 
Although the PROPPR study showed no difference in the primary outcome 
measures there was reduced death from haemorrhage and more rapid haemorrhage 
control in the intervention group (48).  
 
A number of randomised controlled trials in severe traumatic haemorrhage 
investigating a VHA guided approach with use of Factor Concentrates are currently 
underway. The RETIC Trial (Reversal of TIC using Coagulation Factors or Fresh 
Frozen Plasma, NCT01545635) utilised a VHA (ROTEM®) algorithm to guide blood 
product transfusion. The intervention arm received FC and/or PCC in response to 
predefined (ROTEM®) values; the control arm received Plasma transfusion in 
response to the same predefined (ROTEM®) values. Transfusion of PRBC, Platelets 
and TXA was the same in both arms and followed standard institutional clinical 
practise. The primary outcome measure being difference in MOF rates between the 
two groups. This trial has been terminated early after an interim analysis (100 
patients) revealed possible harm to patients randomised to the Plasma arm. The 
STATA Trial (Strategy of Transfusion in Trauma Patients, NCT02416817) is 
comparing a VHA guided approach to a standard fixed ratio MHP. The intervention 
arm will receive Factor Concentrate (FC and PCC) and Platelet resuscitation guided 
by a VHA (ROTEM®) algorithm. The control arm will receive blood product 
transfusion as per a 1:1:1 MHP. The trial is aiming to recruit 200 patients with a 
primary outcome measure of SOFA scores during first 5 days of hospital admission 
and is expected to complete early in 2017. 
Three randomised controlled blinded trials investigating early Fibrinogen 
Concentrate replacement in severe traumatic haemorrhage are currently underway 
or have recently completed; FiiRST (Fibrinogen in the initial Resuscitation of Severe 
Trauma, NTC02203968), E-FIT1 (Early Fibrinogen in Trauma, ISRCTN67540073) 
and PRooF-iTH (Pilot Randomised trial of Fibrinogen in Trauma Haemorrhage, 
NCT02344069).   The FiiRST trial has been completed but not yet published. This 
pilot feasibility study randomised bleeding trauma patients to receive either 6g FC or 
Placebo on admission to the ED with a primary outcome measure being proportion 
of patients receiving intervention within 1 hour of hospital admission.  The E-FIT1 
trial currently recruiting in the UK is also enrolling patients based on clinical likelihood 
of significant haemorrhage with patients randomised to a single dose of 6g FC or 
placebo (in addition to standard MHP) as soon as possible after ED admission. The 
primary outcome measures are feasibility of administering FC within 45 minutes of 
ED admission and the proportion of patients with at least one FibC level ≥ 2g/L 
during active haemorrhage. The PRooF-iTH trial currently recruiting in Copenhagen 
is slightly different from FiiRSt and E-FIT1. This study is again randomising patients 
with traumatic haemorrhage to receiving 60-70mg/Kg FC or placebo immediately 
and pre-emptively on arrival in the ED. The primary outcome is change in TEG FF 
Maximum Amplitude at 15 minutes after intervention. These trials will certainly 
address significant gaps in the evidence base surrounding FC use in severe trauma 
and help plan future studies.  
 
The CRYOSTAT 2 Trial is currently in the planning stages based on the results of 
the pilot feasibility CRYOSTAT trial. CRYOSTAT 2 will be a large, international, 
multi-centre trial in severely bleeding trauma patients investigating fibrinogen 
supplementation using empiric and early cryoprecipitate as part of a MHP, with 
mortality as the primary outcome measure. 
 
Fibrinogen Concentrate vs Cryoprecipitate in Traumatic Haemorrhage: 
 
The large doses of cryoprecipitate utilised in traumatic haemorrhage place a 
significant strain on local blood banks in issuing requested units in a timely manner 
and on national blood supply agencies in maintaining and providing adequate stocks 
to support ABO requirements for individual blood banks. In addition the size and 
population distribution of countries like Australia makes supplying and maintaining 
adequate stocks of ‘fresh’ blood products in remote locations logistically challenging. 
The use of a lyophilised fibrinogen factor concentrate that has a long shelf life and is 
easy to use has enormous implications for both large urban metropolitan areas and 
remote isolated communities. 
 
However, randomised controlled trials are urgently required to investigate the 
haemostatic efficacy of cryoprecipitate compared to fibrinogen concentrate in 
traumatic haemorrhage. A recently published systematic review found sparse 
evidence comparing FC to cryoprecipitate and concluded that it was not possible to 
recommend one product over another in bleeding associated with acquired 
hypofibrinogenaemia (161). It is imperative that robust and clinically relevant studies 
are performed before widespread practice changes are implemented without a solid 
evidence base that would subsequently make performing such studies unfeasible 
(140) (165).  
 
Recently published negative studies investigating the blind administration of 
fibrinogen supplementation in severe haemorrhage combined with the delays in 
fibrinogen replacement utilising MHP or standard laboratory tests potentially justify 
the conduct of a VHA guided trial. Although the inclusion criteria of the FiiRST, E-
FIT1 and PRooF-iTH trials are robust and will identify patients with significant 
haemorrhage, it may not be possible to identify those patients in which 
hypofibrinogenaemia is contributing to on-going TIC associated haemorrhage. It is 
imperative to ensure that the appropriate product is given at the appropriate time in 
the appropriate quantity (157). It is likely that only sustained fibrinogen replacement 
throughout the resuscitation period in tandem with surgical haemorrhage control has 
the potential to impact on hypofibrinogenaemia and TIC (166). The use of a directed 
dosing strategy could inform dose response relationships for both FC and 
cryoprecipitate in terms of plasma fibrinogen increments. Additionally it has been 
suggested that future trauma studies could use admission FIBTEM A5 measures to 
dose adjust fibrinogen replacement (69).   
 
The Fibrinogen Early In Severe Trauma studY (FEISTY, NCT02745041) is a pilot, 
multi-centre, randomised controlled trial comparing FC to cryoprecipitate for 
fibrinogen supplementation in severe traumatic haemorrhage using accepted VHA 
triggers. This pragmatic study expanding on the currently utilised approach at the 
study sites; investigating the feasibility and efficacy of early fibrinogen 
supplementation is the first RCT comparing FC to Cryoprecipitate in traumatic 
haemorrhage. Adult patients with severe trauma and evidence of significant 
haemorrhage will be enrolled on arrival to the trauma unit and randomised to 
receiving fibrinogen supplementation with either FC or cryoprecipitate (Figure 5). The 
primary outcomes are time to administration of fibrinogen supplementation from time 
of ROTEM analysis (and clinical scenario) indicating fibrinogen supplementation is 
required and effects of fibrinogen supplementation on fibrinogen levels. Secondary 
outcomes include; blood product transfusion requirements, thromboembolic 
complications, hospital length of stay and mortality. A number of feasibility outcome 
measures will also be assessed. The study will take place in 4 major Queensland 
trauma centres and is expected to start recruiting in October 2016. The results of 
FEISTY will be used to design a larger and hopefully definitive multi-centre study 
with the aim of addressing patient centred outcomes such as allogenic blood product 
transfusion requirements and mortality. By performing a pilot multi-centre study it is 
hoped to identify logistical issues that could impact on the design and conduct of a 
definitive study and potentially avoid the mistakes made in recently published FC 




Whilst early fibrinogen supplementation with a concentrated product in severe 
traumatic haemorrhage is an attractive therapeutic option, there is currently 
inadequate high-level evidence to support its use. A number of on-going studies are 
currently investigating early fibrinogen replacement in severe trauma. Although the 
majority are pilot feasibility studies they will assist in planning larger definitive trials 
for the benefit of individual patients affected by trauma and for the community as a 
whole. 
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Figure 1. ROTEM Temogram 
Figure 2. EXTEM and FIBTEM Analysis 
Figure 3. GCUH ROTEM Guided Fibrinogen Replacement 
Figure 4. Gunshot Wound Abdomen 





PHASE ROTEM Parameter Coagulation Factor 
INITIATION CT - Clotting Time 
Measured in Seconds 
Pro-Coagulant Factors 
Anti-Coagulant Factors 
KINETICS CFT - Clot Formation Time 





STRENGTH Amplitude after CT 
Measured in mm 
A5 – Amplitude after 5 mins 
A10 – Amplitude after 10 mins 




STABILITY LI (Lysis Index/Residual Clot Firmness) 
Measured in % of MCF 
LI30 – 30 mins after CT 




Activator: CaCl2 + recombinant Tissue Factor 
CT (Clotting Time) - Clotting Factors 
Clot Amplitude (A5/A10/MCF) - Interaction of Fibrinogen and Platelets 
↓ Clot Amplitude EXTEM + Normal FIBTEM = Poor Platelet Contribution 
↑ CT + Normal FIBTEM = Factor Deficiency or Anticoagulants 
FIBTEM: 
Activator: CaCl2 + recombinant Tissue Factor 
Inhibition of Platelet Contribution by addition of Cytochalasin D 
Clot Amplitude (A5/A10/MCF) - Fibrinogen Contribution 
↓ Clot Amplitude FIBTEM = Fibrinogen Deficit or ↓ Fib Polymerisation 
Figure 2
Figure 3
ED Arrival Operating Theatre D1 ICU 
Fig 4. GSW Abdomen 
ED Arrival: Hypotensive, FAST +ve, Lactate 9, BE -14 but Normal ROTEM and Standard Coagulation Tests 
In OT: Visceral, vascular and renal tract injuries with significant haemorrhage 
DCS: Abdomen Packed + Left Open 
Blood product administration guided by ROTEM and utilising FC 
ABG at end of case: pH 7.3, Lactate 3, BE -6  
Total Transfusion 1st 24hrs: 8 PRBC, 4g FC, 10 Units Cryo, 1 Platelet, 1g TXA 
SLT D1: Hb 104, PT 16, Plt 130, Fib 3 
Definitive surgery completed 72 hours after admission  
Figure 4
